{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:43:57Z","timestamp":1784807037985,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clon.2026.104186","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:09:01Z","timestamp":1777964941000},"page":"104186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A Real-World Study: Effect of the Third-Line Therapy of Fruquintinib or Regorafenib Therapy Versus Rechallenge Chemotherapy in Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"55","author":[{"given":"X.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3036-1056","authenticated-orcid":false,"given":"J.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2026.104186_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clon.2026.104186_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.21601","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clon.2026.104186_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO, and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104186_bib4","first-page":"372","article-title":"Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit","volume":"16","author":"Tampellini","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clon.2026.104186_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.clon.2026.104186_bib6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104186_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"109","author":"Modest","year":"2019","journal-title":"Eur J Cancer"},{"issue":"18_suppl","key":"10.1016\/j.clon.2026.104186_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104186_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"Xu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104186_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.clon.2026.104186_bib11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clon.2026.104186_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clon.2026.104186_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104186_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1756-9966-32-92","article-title":"Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer","volume":"32","author":"Tonini","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clon.2026.104186_bib15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.clon.2026.104186_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clon.2026.104186_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-018-3713-6","article-title":"Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?","volume":"83","author":"K\u00f6stek","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.clon.2026.104186_bib18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"29","author":"Arnold","year":"2018","journal-title":"Ann Oncol"},{"issue":"9863","key":"10.1016\/j.clon.2026.104186_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clon.2026.104186_bib21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clon.2026.104186_bib22","first-page":"422","article-title":"Efficacy and safety of cetuximab\/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience","volume":"5","author":"Gebbia","year":"2006","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.clon.2026.104186_bib24","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/ajco.13553","article-title":"Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population","volume":"18","author":"Min","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104186_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.21037\/jgo.2018.04.08","article-title":"Chemotherapy re-challenge response rate in metastatic colorectal cancer","volume":"9","author":"Chambers","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.clon.2026.104186_bib26","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S85567","article-title":"Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study","volume":"9","author":"Suenaga","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.clon.2026.104186_bib27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/cancers14051197","article-title":"Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study","volume":"14","author":"Amatu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clon.2026.104186_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","article-title":"Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study)","volume":"21","author":"Matsuda","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104186_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.cad.0000127144.73043.57","article-title":"Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil","volume":"15","author":"Hartmann","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clon.2026.104186_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/1471-2407-9-347","article-title":"Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study","volume":"9","author":"Li\u00e8vre","year":"2009","journal-title":"BMC Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:25:25Z","timestamp":1781825125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"alternative-id":["S0936655526001573"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104186","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Study: Effect of the Third-Line Therapy of Fruquintinib or Regorafenib Therapy Versus Rechallenge Chemotherapy in Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104186"}}